|
|
Blood, 1 April 2005, Vol. 105, No. 7, pp. 2908-2915.
Prepublished online as a Blood First Edition Paper on December 2, 2004; DOI 10.1182/blood-2004-07-2721.
 Previous Article | Next Article 
Submitted July 16, 2004
Accepted November 25, 2004
High expression of cyclin B1 predicts a favorable outcome of patients with follicular lymphoma
Erik Bjorck, Sara Ek, Ola Landgren, Mats Jerkeman, Mats Ehinger, Magnus Bjorkholm, Carl A Borrebaeck, Anna Porwit-MacDonald*, and Magnus Nordenskjold
Department of Molecular Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
Department of Immunotechnology, Lund University, Lund, Sweden
Department of Medicine, Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
Department of Oncology, Lund University Hospital, Lund, Sweden
Department of Pathology, Lund University Hospital, Lund, Sweden
Department of Pathology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
* Corresponding author; email: anna.mac-donald{at}karolinska.se.
Substantial research has been dedicated to the study of relationship between genetic mechanisms regulating cell functions in tumors and how those tumors respond to various treatment regimens. Because these mechanisms are still not well understood, we have chosen to study the genetic makeup of 57 tumor samples from patients with follicular lymphoma (FL). Our goal was to develop a prognostic tool, which can be used as an aid in determining FL patients with tumors genetically predisposed to a successful treatment with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) regimen. To select relevant genes, high-density oligonucleotide arrays were used. Fourteen genes were highly expressed in FL patients responding well to CHOP chemotherapy and 11 of these were involved in G2/M-transition of the cell cycle, in mitosis or DNA modulation. A high expression of CCNB1 (cyclin B1), CDC2, CDKN3A, CKS1B, ANP32E and KIAA0101, but not of the proliferation related antigen Ki-67 was associated with better survival rate in a univariate analysis. CCNB1 expression had an independent prognostic value when included in a multivariate analysis together with the five parameters of the follicular lymphoma international prognostic index.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Canioni, G. Salles, N. Mounier, N. Brousse, M. Keuppens, F. Morchhauser, T. Lamy, A. Sonet, M.-C. Rousselet, C. Foussard, et al.
High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial
J. Clin. Oncol.,
January 20, 2008;
26(3):
440 - 446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Campana
Molecular Determinants of Treatment Response in Acute Lymphoblastic Leukemia
Hematology,
January 1, 2008;
2008(1):
366 - 373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Flotho, E. Coustan-Smith, D. Pei, C. Cheng, G. Song, C.-H. Pui, J. R. Downing, and D. Campana
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia
Blood,
August 15, 2007;
110(4):
1271 - 1277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Gomez, A. de las Pozas, T. Reiner, K. Burnstein, and C. Perez-Stable
Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy
Mol. Cancer Ther.,
May 1, 2007;
6(5):
1534 - 1543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Wang, J. R. Cerhan, P. Hartge, S. Davis, W. Cozen, R. K. Severson, N. Chatterjee, M. Yeager, S. J. Chanock, and N. Rothman
Common Genetic Variants in Proinflammatory and Other Immunoregulatory Genes and Risk for Non-Hodgkin Lymphoma
Cancer Res.,
October 1, 2006;
66(19):
9771 - 9780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Smith, M. B. Watson, S. L. O'Kane, P. J. Drew, M. J. Lind, and L. Cawkwell
The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays.
Mol. Cancer Ther.,
August 1, 2006;
5(8):
2115 - 2120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ek, U. Andreasson, S. Hober, C. Kampf, F. Ponten, M. Uhlen, H. Merz, and C. A. K. Borrebaeck
From Gene Expression Analysis to Tissue Microarrays: A Rational Approach to Identify Therapeutic and Diagnostic Targets in Lymphoid Malignancies
Mol. Cell. Proteomics,
June 1, 2006;
5(6):
1072 - 1081.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Gascoyne
Hematopathology Approaches to Diagnosis and Prognosis of Indolent B-Cell Lymphomas
Hematology,
January 1, 2005;
2005(1):
299 - 306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
